Tom Needham - Profile and Investment Details

Investor Profile

Tom Needham is a Venture Capital, Private Equity Firm, Investor based in Boston, Massachusetts, United States with a diverse investment portfolio that includes companies such as FineHeart, Provasculon, Laurantis Pharma, DecImmune Therapeutics, Gila Therapeutics, Herantis Pharma, Aria CV, Mosanna Therapeutics, Synthesis Capital, Alveron Pharma, Isomab Ltd, Remedy Pharmaceuticals, Apama Medical, CroíValve, ZZ Biotech, Basking Biosciences Inc, Adient MedicalHAYA Therapeutics, Intravascular Imaging Incorporated, NIDO, G.I. Windows, NuPulseCV, 480 Biomedical, Cardero Therapeutics, Epirium Bio, Allosteros, AtaCor Medical, Alleviant Medical, CardiaLen, Aggamin Biologics, Mellitus, Basking Biosciences, InfoBionic, Vectorious Medical Technologies, Ischemia Care, Capricor Therapeutics, CellAegis Devices, Renovacor, Vascular Graft Solutions, CardiAQ Valve Technologies, Antag Therapeutics, Comanche Biopharma, Ventrinova, Pulmokine, Kantum Bio, BioKier, Zumbro Discovery, Viridian Therapeutics, Acesion Pharma, Aeromics, Longview Ventures, . Over time, Tom Needham has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Tom Needham is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Regenerative Medicine, Wellness, Women Founded, HR Tech, Android, Life Science, Diabetes, Manufacturing, Biotechnology, Tissue Regeneration, Consumer Health, Medical Devices, Electronic Health Records (EHR), Health and Hospital Services, Innovation, Clinical Trials, Research, Gene Therapy, Digital Health, Medical, Information Technology, B2B, Therapeutics, Media and Entertainment, Pharmaceuticals may find it worthwhile to explore potential connections with Tom Needham, as their portfolio suggests a familiarity and interest in this area.

Understanding Tom Needham’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.